1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

GSK's Mekinist recommended in Europe as Novartis looks on

 
• By Sukaina Virji

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Mekinist (trametinib) as a single agent treatment for melanoma with a BRAF V600 mutation. Mekinist is part of GSK's $16bn sale of its oncology division to Novartis through the mega asset swap deal announced earlier this week (scripintelligence.com, 22 April 2014).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Mekinist (trametinib) as a single agent treatment for melanoma with a BRAF V600 mutation. Mekinist is part of GSK's $16bn sale of its oncology division to Novartis through the mega asset swap deal announced earlier this week (scripintelligence.com, 22 April 2014).

Novartis is paying GSK $14.5bn up front and up to $1.5bn contingent on the results of the Phase III COMBI-d...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

More from Therapy Areas

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.